BR112023025528A2 - Peptídeos grampeados e métodos destes - Google Patents

Peptídeos grampeados e métodos destes

Info

Publication number
BR112023025528A2
BR112023025528A2 BR112023025528A BR112023025528A BR112023025528A2 BR 112023025528 A2 BR112023025528 A2 BR 112023025528A2 BR 112023025528 A BR112023025528 A BR 112023025528A BR 112023025528 A BR112023025528 A BR 112023025528A BR 112023025528 A2 BR112023025528 A2 BR 112023025528A2
Authority
BR
Brazil
Prior art keywords
present disclosure
disclosure provides
catenin
beta
methods
Prior art date
Application number
BR112023025528A
Other languages
English (en)
Portuguese (pt)
Inventor
Halbert White Brian
Seungduk La Daniel
L Verdine Gregory
Hanney Mcgee John
Barry Hurov Jonathan
Kevin Ling
Josue Alfaro-Lopez Lorenzo
Robert Tremblay Martin
Cristina Ortet Paula
Peicheng Du
Isabelle Cappucci Sarah
Yaguang Si
Zhi Li
Original Assignee
Fog Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fog Pharmaceuticals Inc filed Critical Fog Pharmaceuticals Inc
Publication of BR112023025528A2 publication Critical patent/BR112023025528A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • C07K7/56—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation not occurring through 2,4-diamino-butanoic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
    • C07K1/1077—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Analytical Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
BR112023025528A 2021-06-08 2022-06-08 Peptídeos grampeados e métodos destes BR112023025528A2 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202163208487P 2021-06-08 2021-06-08
US202163224834P 2021-07-22 2021-07-22
US202263303952P 2022-01-27 2022-01-27
PCT/US2022/032738 WO2022261257A1 (en) 2021-06-08 2022-06-08 Stapled peptides and methods thereof

Publications (1)

Publication Number Publication Date
BR112023025528A2 true BR112023025528A2 (pt) 2024-02-27

Family

ID=84425507

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023025528A BR112023025528A2 (pt) 2021-06-08 2022-06-08 Peptídeos grampeados e métodos destes

Country Status (9)

Country Link
US (1) US20240360179A1 (https=)
EP (1) EP4355350A4 (https=)
JP (1) JP2024522368A (https=)
KR (1) KR20240031957A (https=)
BR (1) BR112023025528A2 (https=)
CA (1) CA3218824A1 (https=)
IL (1) IL308790A (https=)
MX (1) MX2023014679A (https=)
WO (1) WO2022261257A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018329956A1 (en) 2017-09-07 2020-08-20 Fog Pharmaceuticals, Inc. Agents modulating beta-catenin functions and methods thereof
MX2021001943A (es) 2018-08-20 2021-07-15 Fog Pharmaceuticals Inc Colecciones de péptidos, agentes peptídicos y métodos de uso de los mismos.
WO2024130217A1 (en) * 2022-12-15 2024-06-20 Fog Pharmaceuticals, Inc. Stapled peptides and methods thereof
CN120529912A (zh) * 2022-12-15 2025-08-22 帕拉比利斯药物公司 订书钉化肽及其方法
WO2024130224A2 (en) * 2022-12-16 2024-06-20 Purdue Research Foundation Stapled peptides for sensitization of cancer to treatment
KR20260035134A (ko) * 2023-06-06 2026-03-12 파라빌리스 메디슨즈 인코포레이티드 스테이플화 펩티드 및 이의 방법
WO2025265097A1 (en) * 2024-06-20 2025-12-26 Parabilis Medicines, Inc. Stapled peptides and methods thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3549951A3 (en) * 2008-12-09 2019-11-20 Dana Farber Cancer Institute, Inc. Methods and compositions for specific modulation of mcl-1
WO2012040459A2 (en) * 2010-09-22 2012-03-29 President And Fellows Of Harvard College Beta-catenin targeting peptides and uses thereof
EP3391898A3 (en) * 2013-03-13 2019-02-13 President and Fellows of Harvard College Stapled and stitched polypeptides and uses thereof
WO2016085280A1 (ko) * 2014-11-28 2016-06-02 서울대학교산학협력단 세포 투과성 스테이플 펩타이드, 이의 제조방법 및 그 용도
US10011631B2 (en) * 2015-12-01 2018-07-03 The University Of Hong Kong Stapled helical peptides and methods of synthesis
AU2018329956A1 (en) * 2017-09-07 2020-08-20 Fog Pharmaceuticals, Inc. Agents modulating beta-catenin functions and methods thereof
CN117567639A (zh) * 2017-10-27 2024-02-20 俄亥俄州国家创新基金会 用于细胞内递送装订肽的多肽缀合物
MX2021001943A (es) * 2018-08-20 2021-07-15 Fog Pharmaceuticals Inc Colecciones de péptidos, agentes peptídicos y métodos de uso de los mismos.
AU2021314310A1 (en) * 2020-07-22 2023-03-16 Fog Pharmaceuticals, Inc. Stapled peptides and methods thereof

Also Published As

Publication number Publication date
CA3218824A1 (en) 2022-12-15
US20240360179A1 (en) 2024-10-31
KR20240031957A (ko) 2024-03-08
IL308790A (en) 2024-01-01
EP4355350A1 (en) 2024-04-24
WO2022261257A1 (en) 2022-12-15
MX2023014679A (es) 2024-01-15
JP2024522368A (ja) 2024-06-18
EP4355350A4 (en) 2025-10-01

Similar Documents

Publication Publication Date Title
BR112023025528A2 (pt) Peptídeos grampeados e métodos destes
MX2023000947A (es) Peptidos grapados y metodos para su obtencion.
BR112022007627A2 (pt) Compostos moduladores do glp-1r
BR112022017930A2 (pt) Anticorpos anticoronavírus e métodos de uso
BR112023021978A2 (pt) Compostos de carbóxi-benzimidazol moduladores de glp-1r
BR112023021561A2 (pt) Compostos de carbóxi-benzimidazol moduladores de glp-1r
MX2020002435A (es) Agentes que modulan las funciones de beta-catenina y sus métodos.
CO2021007993A2 (es) Compuestos de 2‐formil‐3‐hidroxifeniloximetilo capaces de modular la hemoglobina
PE20141561A1 (es) Anticuerpos anti-lrp5 y metodos de uso
EA202190708A1 (ru) Модуляторы экспрессии pnpla3
CO2018000104A2 (es) Moléculas de anticuerpo que se unen a cd22
BR0209792A (pt) Anticorpos para vla-1
UA130422C2 (uk) Варіант та ізоформа антитіла зі зниженою біологічною активністю
BRPI0517837A (pt) variantes fc com ligação alterada a fcrn
GT200900264A (es) Moléculas y métodos para modular la pro-proteina
MX2012009088A (es) Anticuerpos que se enlazan a lisil oxidasa-tipo2 (loxl2) y metodos de uso para los mismos.
BR112021021645A2 (pt) Anticorpos anti-hvem e uso dos mesmos.
CO2023015915A2 (es) Anticuerpos anti-ccr8
EA200901067A1 (ru) Использование семафорина 6а в качестве промотора миелинизации и дифференцировки олигодендроцитов
ZA202208280B (en) Antibody molecules to c5ar1 and uses thereof
AU2021269176A8 (en) Single domain antibodies binding to SARS-CoV-2 spike protein
BR112019003816A2 (pt) composição de tratamento de enxágue dos cabelos, método para tratamento de cabelos quimicamente danificados e uso de uma composição
BR112014011481A2 (pt) hidrolisado de colágeno e seu uso
JOP20210093B1 (ar) جسم مضاد fn14 غير متوافق مع الإنسان
WO2018119380A3 (en) Design of therapeutic immunoglobulin g4 for improved bioanalytical and bioprocessing properties

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: PARABILIS MEDICINES, INC. (US)